Literature DB >> 18059343

Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs.

T Daubon1, J Chasseriau, A El Ali, J Rivet, A Kitzis, B Constantin, N Bourmeyster.   

Abstract

The chimeric oncogene Bcr-Abl is known to induce autonomous motility of leukemic cells. We show here that p210(bcr-abl) responsible for chronic myelogenous leukemia induces an amoeboid type of motility while p190(bcr-abl), associated with acute lymphoid leukemia, induces a rolling type of motility. We previously reported that p210(bcr-abl) activates RhoA and Rac1, while p190(bcr-abl) although devoid of a Dbl-homology (DH) domain activates Rac1, but not RhoA. We investigated the regulation of GDP/GTP exchange factor (GEF) activities in the Bcr-Abl complex. For that purpose, different GEF activity mutants of Vav and of Bcr-Abl were constructed and stably transfected in Ba/F3 cells. Using these mutants, we demonstrate that RhoA is exclusively activated by the DH domain of p210(bcr-abl), while Rac1 activation is mostly due to Vav. Inhibition of Rac1 by Vav GEF mutant leads to immobilization of cells. Vav depletion using shRNA also induces immobilization of cells and suppression of GTP-bound Rac1. RhoA inactivation induces the specific loss of amoeboid movements. These results suggest that Rac1 activation by Vav triggers the motility of Bcr-Abl-expressing Ba/F3 cells, while the specific amoeboid mode of motility induced by p210(bcr-abl) is a consequence of RhoA activation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18059343     DOI: 10.1038/sj.onc.1210933

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.

Authors:  J A Cutler; R Tahir; S K Sreenivasamurthy; C Mitchell; S Renuse; R S Nirujogi; A H Patil; M Heydarian; X Wong; X Wu; T-C Huang; M-S Kim; K L Reddy; A Pandey
Journal:  Leukemia       Date:  2017-02-17       Impact factor: 11.528

2.  RhoA: a therapeutic target for chronic myeloid leukemia.

Authors:  Poonam R Molli; Madhura B Pradhan; Suresh H Advani; Nishigandha R Naik
Journal:  Mol Cancer       Date:  2012-03-25       Impact factor: 27.401

Review 3.  Leukaemia: a model metastatic disease.

Authors:  Andrew E Whiteley; Trevor T Price; Gaia Cantelli; Dorothy A Sipkins
Journal:  Nat Rev Cancer       Date:  2021-05-05       Impact factor: 69.800

4.  Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.

Authors:  S Gerboth; E Frittoli; A Palamidessi; F C Baltanas; M Salek; J Rappsilber; C Giuliani; F Troglio; Y Rolland; G Pruneri; S Kreutmair; I Pallavicini; M Zobel; M Cinquanta; S Minucci; C Gomez; E Santos; A L Illert; G Scita
Journal:  Leukemia       Date:  2017-08-18       Impact factor: 11.528

5.  Niche WNT5A regulates the actin cytoskeleton during regeneration of hematopoietic stem cells.

Authors:  Christina Schreck; Rouzanna Istvánffy; Christoph Ziegenhain; Theresa Sippenauer; Franziska Ruf; Lynette Henkel; Florian Gärtner; Beate Vieth; M Carolina Florian; Nicole Mende; Anna Taubenberger; Áine Prendergast; Alina Wagner; Charlotta Pagel; Sandra Grziwok; Katharina S Götze; Jochen Guck; Douglas C Dean; Steffen Massberg; Marieke Essers; Claudia Waskow; Hartmut Geiger; Mathias Schiemann; Christian Peschel; Wolfgang Enard; Robert A J Oostendorp
Journal:  J Exp Med       Date:  2016-12-20       Impact factor: 14.307

6.  An end-to-end software solution for the analysis of high-throughput single-cell migration data.

Authors:  Paola Masuzzo; Lynn Huyck; Aleksandra Simiczyjew; Christophe Ampe; Lennart Martens; Marleen Van Troys
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

7.  Increased cytoplasmic localization of p27(kip1) and its modulation of RhoA activity during progression of chronic myeloid leukemia.

Authors:  Anita Roy; Lakshmishri Lahiry; Debasis Banerjee; Malay Ghosh; Subrata Banerjee
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

8.  Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.

Authors:  I Tala; R Chen; T Hu; E R Fitzpatrick; D A Williams; I P Whitehead
Journal:  Leukemia       Date:  2012-12-04       Impact factor: 11.528

9.  Trading in your spindles for blebs: the amoeboid tumor cell phenotype in prostate cancer.

Authors:  Samantha Morley; Martin H Hager; Sara G Pollan; Beatrice Knudsen; Dolores Di Vizio; Michael R Freeman
Journal:  Asian J Androl       Date:  2014 Jul-Aug       Impact factor: 3.285

10.  Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia.

Authors:  Hélène Cabanas; Thomas Harnois; Christophe Magaud; Laëtitia Cousin; Bruno Constantin; Nicolas Bourmeyster; Nadine Déliot
Journal:  Oncotarget       Date:  2018-05-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.